Report results from Phase 3 INVIGORATE-2 trial of reproxalap

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 17 Mar 2022
Due: 31 Dec 2023
Delivered: June 2023

Deadline
Met
Late
Not met
Today

What the company said

“Results from INVIGORATE-2 are expected in 2023.”

SourceAldeyra Therapeutics, Inc. Form 8-K press release, 2022-03-17
FilingSEC filing index
Deadline as statedin 2023
Deadline used31 Dec 2023, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2022-ALDX-003455
Cite as https://keptindex.org/c/KI-C-2022-ALDX-003455/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced the results of the Phase 3 INVIGORATE-2 trial in June 2023, confirming that the trial met its primary and secondary endpoints.

A
Aldeyra Therapeutics, Inc. 10-K filed 2024-03-07 Regulatory filing · published 7 Mar 2024 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint 09dce78708ec
“In June 2023, we announced that INVIGORATE-2, a confirmatory clinical trial substantially similar to INVIGORATE, achieved the primary endpoint” ✓ confirmed on the page

Market reaction: the shares moved -17.6% against the S&P 500 over the three sessions around the disclosure (6 Mar 2024 to 11 Mar 2024). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift -184 days
2 versions

Version 1 · original · stated 17 Mar 2022

Deadline 31 Dec 2023 (“in 2023”) · wording expected
Version 2 · stated 4 May 2023

Deadline 30 Jun 2023 (“the Second Quarter of 2023”) · wording expected

“Top-Line Results from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis Expected in the Second Quarter of 2023”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: Phase 3 INVIGORATE-2 trial results
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.